Premium
Will chemotherapy change the management of prostate cancer?
Author(s) -
Gilson Clare,
Sydes Matthew R.,
Chowdhury Simon
Publication year - 2016
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13400
Subject(s) - medicine , clinical trial , unit (ring theory) , library science , psychology , mathematics education , computer science
Systemic therapy for metastatic prostate cancer has radically changed in the last 10 years with the introduction of several novel agents that have shown significant improvements in progression-free (PFS) and overall survival (OS), see Table 1. These have largely been studied in metastatic castrate refractory prostate cancer (mCRPC) and have prolonged survival but in each case by less than 6 months [1]. The initial treatment of prostate cancer has not significantly changed since Huggins and Hodges first demonstrated the effects of castration and androgen deprivation which remains the mainstay of systemic treatment. However, the latest breakthrough in the treatment of metastatic disease is the introduction of a relatively old drug, docetaxel chemotherapy, earlier in the disease for hormone-sensitive patients.